- Home
- EARN vs BDTX Comparison
EARN vs BDTX Comparison
Compare EARN & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EARN
- BDTX
- Stock Information
- Founded
- EARN 2012
- BDTX 2014
- Country
- EARN United States
- BDTX United States
- Employees
- EARN N/A
- BDTX N/A
- Industry
- EARN Real Estate Investment Trusts
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EARN Real Estate
- BDTX Health Care
- Exchange
- EARN Nasdaq
- BDTX Nasdaq
- Market Cap
- EARN 223.5M
- BDTX 181.4M
- IPO Year
- EARN 2013
- BDTX 2020
- Fundamental
- Price
- EARN $5.67
- BDTX $2.59
- Analyst Decision
- EARN Buy
- BDTX Strong Buy
- Analyst Count
- EARN 2
- BDTX 6
- Target Price
- EARN $6.13
- BDTX $14.83
- AVG Volume (30 Days)
- EARN 321.1K
- BDTX 911.7K
- Earning Date
- EARN 08-11-2025
- BDTX 08-05-2025
- Dividend Yield
- EARN 16.96%
- BDTX N/A
- EPS Growth
- EARN N/A
- BDTX N/A
- EPS
- EARN N/A
- BDTX 0.09
- Revenue
- EARN $35,893,000.00
- BDTX $70,000,000.00
- Revenue This Year
- EARN $3.72
- BDTX N/A
- Revenue Next Year
- EARN $18.60
- BDTX N/A
- P/E Ratio
- EARN N/A
- BDTX $29.29
- Revenue Growth
- EARN 43.30
- BDTX N/A
- 52 Week Low
- EARN $4.33
- BDTX $1.20
- 52 Week High
- EARN $7.11
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- EARN 38.67
- BDTX 41.44
- Support Level
- EARN $5.88
- BDTX $2.73
- Resistance Level
- EARN $6.06
- BDTX $2.97
- Average True Range (ATR)
- EARN 0.11
- BDTX 0.19
- MACD
- EARN -0.03
- BDTX -0.08
- Stochastic Oscillator
- EARN 7.78
- BDTX 8.81
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics, and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.